Finanzen von Adial Pharmaceuticals Inc (ADIL)ADILAdial Pharmaceuticals Inc

In the context of the broader market, ADIL competes directly with industry leaders such as LTRN and TPST. With a market capitalization of $13.28M, it holds a leading position in the sector. When comparing efficiency, ADIL's gross margin of N/A stands against LTRN's N/A and TPST's N/A. Such benchmarking helps identify whether Adial Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Adial Pharmaceuticals has faced considerable financial challenges, with net income losses ranging from approximately $1.8 million to $52 million over the last quarters. The current ratio is strong at 5.63, indicating good short-term financial health despite ongoing losses.